Making Cents: Recent Episodes
Red Thread Ventures
Finances are one of the most overwhelming concepts for young people to wrap their heads around. With the risks that come with investing and seemingly high barriers to entry, many young people are initially turned off when they think of all things finance. Well that is where we come in
We are here to help your money make cents! Hosted by university students and Intern Analysts at Red Thread Ventures, Making Cents will feature in-depth interviews with professionals from a wide range of industries like cleantech to fintech, alongside investing and internship tips and tricks.
We had a chance to sit down with our friend Chris Robson for a deep dive into startup fundraising. Chris is the CEO & Co-founder at Edmonton based Wyvern, a space data company enabling next-generation earth observation using hyper-spectral cameras.
If you're an entrepreneur thinking about that first raise, be sure to listen in as Chris shares some of his learnings after successfully raising $17.M in capital from some of North America's top seed investors including MaC Venture Capital, Uncork Capital, Y-Combinator, and Soma Capital.
We were fortunate enough to participate in Wyvern's early rounds of financing through our angel syndicate Red Thread Ventures and our venture capital firm Weave VC and have been amazed at their progress over the past few years!
For more information on Wyvern and their offerings, please visit them online at https://wyvern.space/
Today’s guest is Dr. Mads Daugaard. Mads is the Co-founder, President and Chief Scientific Officer at Canadian cancer therapeutics company, Rakovina Therapeutics, a Red Thread Ventures portfolio company. This is his third time on our podcast and in today’s session we focused on Rakovina’s 2022 progress, their partnership with the St.Baldrick's foundation, distinctions between first generation/next generation therapies, and their push to IND filing and human clinical trials. We hope you enjoy today’s discussion with Dr. Mads Daugaard!
Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatoryagencies. Further information can be found at www.rakovinatherapeutics.com, on LinkedIn, and on Twitter @rakovina_rkv.
Red Thread Ventures has featured Rakovina in multiple blog posts, head over to www.redthread.ventures/blog to learn more.
Dr. Mads Daugaard is the Co-founder, President and Chief Scientific Officer at biotech company, Rakovina Therapeutics. Founded in 2020, Rakovina is striving to revolutionize cancer treatment and extend the lives of cancer patients. Not yet in human clinical trials, they are developing medicines that selectively target and kill cancer cells using leading-edge science that we’ll discuss with Mads in this episode. The therapeutics company has 3 research programs, Kt-2000, 3000 and 4000, all of which are in the preclinical stage of drug development. Rakovina is currently being traded on the TSX Venture Exchange under the symbol RKV.
On April 8th in New Orleans, Mads is attending the American Association for Cancer Research or AACR annual meeting, which is the largest cancer research conference. Following that he is sharing an abstract highlighting Rakovina’s KT-3000 series at AACR’s special conference on Sarcoma cancer in Montreal. The episode highlights why it is so important for Rakovina and other preclinical biotech companies to attend conferences like these.
To learn more about Rakovina's presentation at the AARC conference, you can view their press release here.
To continue your dive into biotech investing, check out this blog series featuring Rakovina: Myths and Risks in Biotech Investing
Rakovina Therapeutics
Website
Red Thread Ventures
Website
Youtube
On today's episode, we sit down with Doctor Mads Daugaard, the President and Chief Scientific Officer at Rakovina Therapeutics. Mads is a molecular biologist who earned his PhD degree from the Faculty of Health Sciences, University of Copenhagen, for his studies on heat shock proteins in relation to cancer cell survival mechanisms. He is also Head of the Molecular Pathology and Cell Imaging Unit, Senior Research Scientist at Vancouver Prostate Centre, and associate Professor at Department of Urologic Sciences, University of British Columbia.
Check out this episode to learn more about biotech industry, preclinical research, and the impressive waves that Rakovina Therapeutics are creating in the oncology space.
On today's episode, we sit down with Mark Mitchell, the Principle and Director of Red Thread Ventures, the investment firm where we work; Mark is also the Co-Founder at IPEX. Mark has had the pleasure of travelling around the world and building connections, while simultaneously building up his portfolio of experiences. More specifically, he has immersed himself with business in China (he is even fluent in Mandarin too!). Through our conversation, we learn more about the benefits of conducting business internationally as well as the Dos and Don'ts of networking. Mark's tips apply to everyone, whether you are a student or a seasoned professional, so you won't want to miss it!
We have an expected guest for today's episode, Xin Zheng, otherwise known as Prof X to us. Prof X was our financial accounting professor this summer and is a passionate individual who was always sharing fun investing stories during class. During our discussion, we talk about what it means to be a fundamentals-based investor, his current hot stock and some advice to beginner investors. This episode is a personal favourite, and we hope you have fun and learn a lot!
On today's episode, we have Marc Wandler, the CEO and Co-Founder of Susgrainable, a Vancouver-based health food company. Susgrainable leverages technology and partnerships to create an Upcycled Barley Flour from what was previously considered waste in the beer industry. He is continually redefining what it means to have a sustainable business model with the vision to create a world where food waste and diabetes are a thing of the past. We are excited to hear about Marc's journey and his continued path into developing a circular economy, so let's dive right in!
We are back with another episode! This week, we are covering a topic that we haven’t discussed before, and one we are not too familiar with ourselves: gold, bonds and inflation. We felt that these topics weren’t talked about enough, and we wanted to provide a resource for those who wanted a breakdown of these topics so we invited Anders Kruus, a knowledgeable industry professional, to educate us on the basics of investing in this space.
Feel free to contact Anders at akruus@gmail.com to access more valuable resources!
As intra-preneurs and aspiring entrepreneurs, we are so lucky to have gotten the opportunity to have an entrepreneurial-focussed conversation with Tania Lo. Tania is the CEO and Co-Founder of Tandem Innovation Group where she convenes a network of over 150 growth advisors, contract CFOs, COOs and many more individuals, and connects them with startups and growing companies. Tania is also the Co-Founder of TheVenture.Fund and is passionate about women-led entrepreneurship, a topic of discussion we are extremely passionate about too.
This episode is packed with great insights and resources, so what are you waiting for? Press play and get ready to learn!
After hearing GotCare's compelling and purpose-driven pitch during our internship, we knew that we had to have an entrepreneurial-focussed conversation with Chenny Xia, the CEO and Co-Founder of GotCare, a health-tech company focussed on transforming home care. Listen in as we learn about Chenny's journey as a female entrepreneur, keys to a great pitch presentation and her best leadership practices when managing her dream team.
BitClout, a new way of investing caught our attention after learning about its appeal of combining speculation and social media. Instead of investing in companies, BitClout enables users to invest in their favourite influencers, including Elon Musk, Kim Kardashian and Barack Obama. Dependent almost entirely on reputation, BitClout seems to be the newest, modern way of investing. Is BitClout a fad or the future of investing? Listen in to hear what we think!
We are super excited to debut our first guest episode with Marco Donadeo. Marco is a Director at Red Thread Ventures with expansive experience in private equity. He started off investing in the public markets when he was 12, before discovering his passion for private equity. Listen in as we learn more about what the signs are of a good business model, what exactly it means to be an accredited investor, and many more valuable insights!
The distinction between private and public equity can be confusing, two forms of investing that sound similar, but are totally different. In this episode, we clarify the distinction between the two, and give insight into which may be for you and your investment needs. Additionally, we debunk some of the myths surrounding private equity to prove that the barriers to this form of investing aren’t as intimidating as they seem. Stay tuned to this short n’ sweet episode, which is a little teaser into an upcoming episode with a special guest.
*Clarifying note: within public equity, you are not able to trade 24/7, any orders filled after hours will be fulfilled once the market opens again the next working day
What do two young girls know about investing? Not a lot! That's why Emma and Carmen are perfect hosts to break down the barriers to investing and provide you with key tips to make the most out of your portfolio. From investing in companies that interest you and maintaining a diversified portfolio, Emma and Carmen, business students from the University of British Columbia will recount their early learnings as interns at Red Thread Ventures, an investment and advisory firm.